Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer

@article{HernndezGarca2015EffectOO,
  title={Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer},
  author={Susana Hern{\'a}ndez-Garc{\'i}a and V. Negron Gonzalez and Eduardo Sanz and Atanasio Pandiella},
  journal={Nutrition and Cancer},
  year={2015},
  volume={67},
  pages={1159 - 1169}
}
One of the most aggressive breast cancer subtypes includes tumors with high expression of HER2. [] Key Method Dose-response studies, biochemical and cytometric assessment of the effect of OOS on cell cycle and apoptosis, and drug combination analyses were performed on BT474 and SKBR3 cells, 2 HER2-overexpressing breast cancer cell lines. OOS reduced the proliferation of these cells, and augmented the action of lapatinib, a HER2 inhibitor used in the breast cancer clinic. Moreover, OOS decreased growth of…
View on Taylor & Francis
digital.csic.es
14 Citations
Background Citations
9
Methods Citations
1
Results Citations
2

14 Citations

Citation Type

Citation Type

Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer
TLDR
The results suggest that OOS has antitumoral action on SCLC, and could be used to supplement the action of drugs commonly used to treat this type of tumor.
Ocoxin® oral solution slows down tumor growth in an experimental model of colorectal cancer metastasis to the liver in Balb/c mice
TLDR
OOS reduced the metastatic development of colorectal cancer to the liver by increasing apoptosis, and decreasing tumor cell proliferation and fibroblast recruitment in the tumor foci, as well as the expression of inflammatory mediators in total liver.
Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin
TLDR
In in vivo models of acute myelogenous leukemia and small-cell lung cancer, it is suggested that the antitumoral effect of OOS is due to blockade of cell cycle progression mainly caused by the action of Oos on the E2F–TFDP pathway.
Antitumoral effect of Ocoxin in hepatocellular carcinoma
TLDR
OOS inhibited the proliferation of HCC cell lines in a time- and dose-dependent manner, being more efficient when used in combination with sorafenib, a standard of care treatment for patients diagnosed with advanced-stage disease.
Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver
TLDR
OOS®, when administered as a complement to irinotecan, reduced the metastatic development of colorectal cancer to the liver and point out OOS® as a potential supplement to the anti-tumoral treatments used in clinical settings in patients suffering from disseminated coloreCTal cancer.
Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma
TLDR
How OOS affects stem cell properties in certain GBMs, slowing down their tumor growth is described, and OOS has a direct effect on macrophage polarization in vitro and in vivo, inhibiting the protumoral features of M2 macrophages.
Antitumoral effect of Ocoxin on acute myeloid leukemia
TLDR
When tested in combination with other therapeutic agents normally used in the treatment of AML patients, OOS demonstrated a higher antiproliferative action, suggesting that it may be used in conjunction with those standard of care treatments to potentiate their anti-AML action in the AML clinic.
Ocoxin as a complement to first line treatments in cancer
TLDR
Ocoxin, a plant extract and natural compound based nutritional complement rich in antioxidants and anti-inflammatory mediators exerts a positive effect in patients receiving chemotherapy and radiotherapy, and has been proven to be effective as anticancer agent in different tumor models both in vitro and in vivo.
Microenvironmental Reactive Oxygen Species in Colorectal Cancer: Involved Processes and Therapeutic Opportunities
TLDR
This review will examine the main ROS producer cells and their effects on cancer progression and metastasis, and enumerate the latest clinical trials where pro-oxidants and antioxidants have therapeutic uses in CRC.
Efficacy and Safety of Oncoxin-Viusid, a Nutritional Supplement, in Twenty Patients with Stage IIB-III of Cutaneous Melanoma: An open-Label Proof of Concept Study
  • Medicine
  • 2019
TLDR
This study aimed to identify the efficacy and safety of the Oncoxin-Viusid as an adjuvant treatment for patients with stage IIB-III cutaneous melanomas and showed safety, and patients kept a stable quality of life and a high progression-free survival rate.
...
1
2
...

References

SHOWING 1-10 OF 45 REFERENCES
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
TLDR
It is reported that concentration-dependent antiproliferative effects of lapatinib were seen in all breast cancer cell lines tested but varied significantly between individual cell lines with up to 1,000-fold difference in the IC(50)s (range, 0.010-18.6 micromol/L).
Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-kappaB signaling in HER2-overexpressing breast cancer cells.
TLDR
Genistein and quercetin exert their antiproliferative activity by inhibiting NFκB signaling in HER2-overexpressing breast cancer cells.
Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.
TLDR
The spectrum of patients who may benefit from trastuzumab-based therapies may be widened to include patients with metastatic breast cancer without HER-2 amplification but who express transmembrane NRGs.
Treatment of HER2-positive breast cancer: current status and future perspectives
TLDR
This Review focuses on current treatment for patients with HER2-positive breast cancer and aims to update practicing clinicians on likely future developments in the treatment for this disease according to ongoing clinical trials and translational research.
Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells
TLDR
The results demonstrate that when HER2-targeted immunoliposomes are coupled to trastuzumab there is a dramatic increase in the antiproliferative effects of curcumin and resveratrol in HER2 positive human breast cancer cells in comparison to regular liposomed or free forms, indicating an increase of its therapeutic effect.
Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway.
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
TLDR
The association between the inhibition of survivin and enhanced apoptosis following the combination of ErbB2-targeted therapies provides a biological effect in order to identify therapeutic strategies that promote tumor cell apoptosis and might improve clinical response.
Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target
TLDR
It is found that inhibition of Erk5 decreased cancer cell proliferation and also sensitized these cells to the action of anti-HER2 therapies, and may represent a future therapeutic target.
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
TLDR
The data suggest that lapatinib is a promising agent for the prevention of ER-negative breast cancer and that cyclin D1, epiregulin, and p27 may represent useful biomarkers of lapatinIB response in patients.
Cinnamic acid: A natural product with potential use in cancer intervention
TLDR
It is shown that cinnamic acid induces cytostasis and a reversal of malignant properties of human tumor cells in vitro, and molecular analysis indicated that the anti‐tumor activity of cinnic acid may be due in part to the inhibition of protein isoprenylation known to block mitogenic signal transduction.
...
1
2
3
4
5
...